Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:CORSNASDAQ:GWIINASDAQ:IQMDNASDAQ:SNTI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCORSCorsair Partnering$10.37$10.35$9.68▼$10.60$308.33M0.02128,468 shs13 shsGWIIGood Works II Acquisition$10.11$10.16$9.81▼$12.00$89.68M-0.022,195 shsN/AIQMDIntelligent Medicine Acquisition$11.04$10.72$9.97▼$11.22$64.75M0.0348,072 shsN/ASNTISenti Biosciences$5.00+2.7%$3.54$1.52▼$16.94$126.64M2.32788,914 shs35,535 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCORSCorsair Partnering0.00%0.00%0.00%0.00%0.00%GWIIGood Works II Acquisition0.00%0.00%0.00%0.00%0.00%IQMDIntelligent Medicine Acquisition0.00%0.00%0.00%0.00%0.00%SNTISenti Biosciences+2.67%+28.87%+40.85%+5.93%+78.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCORSCorsair PartneringN/AN/AN/AN/AN/AN/AN/AN/AGWIIGood Works II AcquisitionN/AN/AN/AN/AN/AN/AN/AN/AIQMDIntelligent Medicine AcquisitionN/AN/AN/AN/AN/AN/AN/AN/ASNTISenti Biosciences2.9074 of 5 stars3.53.00.00.02.81.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCORSCorsair Partnering 0.00N/AN/AN/AGWIIGood Works II Acquisition 0.00N/AN/AN/AIQMDIntelligent Medicine Acquisition 0.00N/AN/AN/ASNTISenti Biosciences 3.00Buy$10.00100.00% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCORSCorsair PartneringN/AN/A$0.44 per share23.37($0.49) per shareN/AGWIIGood Works II AcquisitionN/AN/AN/AN/A$0.07 per shareN/AIQMDIntelligent Medicine AcquisitionN/AN/AN/AN/AN/AN/ASNTISenti Biosciences$2.56M50.79N/AN/A$15.02 per share0.33Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCORSCorsair Partnering$13.19MN/A0.00∞N/AN/A-80.72%3.55%N/AGWIIGood Works II Acquisition-$500KN/A0.00∞N/AN/A-22.76%-0.17%N/AIQMDIntelligent Medicine AcquisitionN/AN/A0.00∞N/AN/AN/AN/AN/ASNTISenti Biosciences-$71.06M-$12.03N/AN/AN/AN/A-154.84%-77.42%5/8/2025 (Estimated)Latest SNTI, GWII, IQMD, and CORS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/20/2025Q4 2024SNTISenti Biosciences-$3.13-$0.67+$2.46-$0.67$2.80 million$5.86 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCORSCorsair PartneringN/AN/AN/AN/AN/AGWIIGood Works II AcquisitionN/AN/AN/AN/AN/AIQMDIntelligent Medicine AcquisitionN/AN/AN/AN/AN/ASNTISenti BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCORSCorsair PartneringN/A0.490.49GWIIGood Works II AcquisitionN/A2.622.62IQMDIntelligent Medicine AcquisitionN/AN/AN/ASNTISenti BiosciencesN/A1.921.92Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCORSCorsair Partnering80.11%GWIIGood Works II AcquisitionN/AIQMDIntelligent Medicine Acquisition56.63%SNTISenti Biosciences25.73%Insider OwnershipCompanyInsider OwnershipCORSCorsair PartneringN/AGWIIGood Works II Acquisition4.60%IQMDIntelligent Medicine Acquisition0.48%SNTISenti Biosciences10.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCORSCorsair Partnering2,02129.74 millionN/ANot OptionableGWIIGood Works II Acquisition2,0218.87 million8.47 millionNot OptionableIQMDIntelligent Medicine Acquisition2,0215.87 million5.84 millionNot OptionableSNTISenti Biosciences426.00 million4.30 millionNot OptionableSNTI, GWII, IQMD, and CORS HeadlinesRecent News About These CompaniesSenti Biosciences to Host Conference Call on SENTI-202 Phase 1 Clinical Data Ahead of AACR Annual MeetingApril 26 at 7:30 PM | nasdaq.comWhy Senti Biosciences, Inc.’s (SNTI) Stock Is Up 5.44%April 25 at 2:46 AM | aaii.comSenti Bio to Host Conference Call and Webcast to Discuss SENTI-202 Clinical Data Being Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 on Monday, April 28th at 8:30 AM ETApril 24 at 8:35 AM | globenewswire.comSenti Biosciences Releases KOL Segment Featuring Dr. Stephen Strickland on Advances in Acute Myeloid Leukemia ResearchApril 21, 2025 | quiverquant.comSenti Bio Participates in a Virtual Investor KOL Connect SegmentApril 21, 2025 | globenewswire.comSenti Biosciences, Inc. (NASDAQ:SNTI) Short Interest UpdateApril 19, 2025 | marketbeat.comSenti Bio (NASDAQ: SNTI) to Participate in a Live Virtual Investor Closing Bell SegmentApril 16, 2025 | globenewswire.comWhy Senti Biosciences, Inc.’s (SNTI) Stock Is Up 8.89%April 11, 2025 | aaii.comSenti Bio appoints James Trager to Scientific Advisory BoardApril 11, 2025 | markets.businessinsider.comSenti Bio Bolsters Scientific Advisory Board with Appointment of James B. Trager, Ph.D.April 10, 2025 | globenewswire.comSenti Bio Bolsters Scientific Advisory Board with Appointment of James B. Trager, Ph.D.April 10, 2025 | globenewswire.comSenti Biosciences joins Webull’s Corporate Connect ServiceApril 9, 2025 | uk.investing.comWhy Senti Biosciences, Inc.’s (SNTI) Stock Is Up 8.41%April 9, 2025 | aaii.comSenti Bio Joins Webull Corporate Connect Service PlatformApril 7, 2025 | globenewswire.comSenti Bio to Showcase SENTI-202 Clinical Data and Novel Logic Gated Gene Circuit Mechanism of Action in Oral and Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2025April 3, 2025 | globenewswire.comSenti Bio files $300M mixed securities shelfMarch 21, 2025 | markets.businessinsider.comSenti Bio files to sell 52.9M shares of common stock for holdersMarch 21, 2025 | markets.businessinsider.comSenti Biosciences, Inc.: Senti Bio Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Pipeline and Corporate HighlightsMarch 21, 2025 | finanznachrichten.deSenti Bio reports Q4 EPS (67c), consensus ($3.13)March 21, 2025 | markets.businessinsider.comSenti Bio Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Pipeline and Corporate HighlightsMarch 20, 2025 | globenewswire.comSenti Bio appoints new board member, grants stock optionsMarch 15, 2025 | investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSNTI, GWII, IQMD, and CORS Company DescriptionsCorsair Partnering NYSE:CORSCorsair Partnering Corporation does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar partnering transaction with one or more businesses. Corsair Partnering Corporation was incorporated in 2020 and is based in New York, New York.Good Works II Acquisition NASDAQ:GWIIGood Works II Acquisition Corp. does not have significant operations. It focuses on effecting a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities. The company was incorporated in 2020 and is based in Houston, Texas.Intelligent Medicine Acquisition NASDAQ:IQMDIntelligent Medicine Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or related business combination with one or more businesses. It intends to identify business opportunities in the field of life science. The company was incorporated in 2021 and is based in Bethesda, Maryland.Senti Biosciences NASDAQ:SNTI$5.00 +0.13 (+2.67%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$4.89 -0.11 (-2.10%) As of 04/25/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 04/21 - 04/25 Bears Can Reap Big Benefits With These 3 Short ETF Bets If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy 3 Stocks To Watch For When Tariffs Subside 3 Boring Stocks Outperforming the Market This Year Short Sellers Gave Up on These 3 Names Recently Churchill Downs Stock: Could Tariff Fears Dampen Derby Gains? Markets Think Robinhood Earnings Could Send the Stock Up Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
